{"nctId":"NCT01408537","briefTitle":"Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children","startDateStruct":{"date":"2010-05"},"conditions":["Encephalitis, Japanese B"],"count":152,"armGroups":[{"label":"JEVAC","type":"EXPERIMENTAL","interventionNames":["Biological: JEVAC"]}],"interventions":[{"name":"JEVAC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy Thai children aged 1- 3 years\n2. No previous history of JE vaccination\n3. Available for all visited schedule in the study period.\n4. Written inform consent signed by a parent or guardian\n\nExclusion Criteria:\n\n1. Known serious underlying diseases such as nervous system, heart, kidney and liver diseases.\n2. Known hypersensitivity to JE vaccine composition such as human albumin, dextran 40, etc.\n3. Previous history of JE disease.\n4. Receive the blood component within the past 3 months,\n5. Known history of immunocompromised conditions such as HIV/AIDS, malignancy.\n6. Under treatment of immunosuppressive drugs such as systemic corticosteroid and anti-neoplastic drug.\n7. Febrile illness (temperature ≥37.5°C) or acute illness/infection on the day of vaccination\n8. Plan to leave the study area before the end of study period.\n9. Participating in other clinical trials.","healthyVolunteers":true,"sex":"ALL","minimumAge":"1 Year","maximumAge":"3 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seroconversion Rate After Primary Vaccination","description":"To determine the seroconversion rate by using neutralizing antibody (NT) against JE virus (Beijing P3 strain) JE virus from \\<10 on before first vaccination To \\>= 10 at 28 days after second vaccination (primary vaccination). Those who have NT titer \\>=10 before first vaccination, will not be included in immunogenicity evaluation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer of NT After Primary and Booster Vaccination","description":"To determine the geometric mean titers (GMT) of neutralizing antibody of JEVAC 1 month after primary and then before and after booster vaccinations.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150.01","spread":null},{"groupId":"OG001","value":"49.33","spread":null},{"groupId":"OG002","value":"621.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events of Vaccine","description":"To determine the adverse events of JEVAC","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"24","spread":null},{"groupId":"OG004","value":"36","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"63","spread":null},{"groupId":"OG007","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Neutralizing Antibody Persistence One Year After the Primary Vaccination","description":"To determine the neutralizing antibody persistence one year after the primary JEVAC vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":152},"commonTop":["Fever","vomiting","upper respiratory tract infection","poor appetite","contact dermatitis"]}}}